XCell Therapeutics Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Vol. 1Y

—

Shs. 5Y

—

Rev. 5Y

29.26%

Div Yld LY

—

Div Yld TTM

—

Revenues

1.95b

+0.76%

Net income

-10.93b

L+14.50%

CFO

-9.50b

L+35.81%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.

URL

http://www.xcell.media/

IPO date

Jul 15, 2024

Employees

Domiciled in

Incorporated in

Valuation

Latest on right Latest on left

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT